Meet Adnan T. Savera, MD

Medical Director, NJU Diagnostics

Medical School

Dow Medical College – Karachi, Pakistan

Internship & Residency

  • Surgical Unit Internship, Civil Hospital – Karachi, Pakistan
  • Internal Medicine Internship, Howard University Hospital – Washington, D.C.
  • Pathology Residency, Henry Ford Hospital – Detroit, MI

Languages Spoken

English

Ages Served

18+

Dr. Adnan Savera is a nationally recognized GU pathologist with a unique expertise and wealth of experience in this field. As a Senior Staff Physician at Henry Ford Hospital in Detroit, Dr. Savera led GU pathology services and research for their globally acclaimed Vattikuti Urology Institute. He was instrumental in creating an innovative GU pathology/consultation service to support the launch and growth of the world’s largest robotic prostatectomy program. Dr. Savera has also served as Chief Medical Officer and Director of GU Pathology for PLUS Diagnostics, a national commercial lab that, during his tenure, served one of the largest urology client bases.

Dr. Savera currently serves as the Medical Director of NJU Diagnostics. He has participated in numerous NIH funded grants and presented at national and international scientific meetings. He has been recognized by the U.S. Department of Health and Human Services for his contributions to the field of prostate cancer and is listed among America’s Top Physicians by the Consumer Research Council of America.

Dr. Savera completed his pathology residency at Henry Ford Hospital and oncologic pathology fellowship at Memorial Sloan-Kettering Cancer Center in New York. He has authored more than 70 peer-reviewed papers and abstracts reporting ground breaking research work and revolutionary treatments of prostate cancer. Board certified in anatomic pathology, Dr. Savera is an elected Fellow of the International Society of Urological Pathology and College of American Pathologists and a member of the American Urological Association.

SPECIALTIES

  • Oncologic Pathology
  • Urologic Pathology
  • Head & Neck Pathology
  • Breast Pathology

NJU Diagnostics
1515 Broad Street
Suite B130
Bloomfield, NJ 07003

  • American Urological Association (AUA)
  • College of American Pathologists (CAP)
  • International Society of Urologic Pathologists (ISUP)
  • US and Canadian Academy of Pathology (USCAP)
  • Outstanding Resident Award, Department of Pathology, Henry Ford Hospital (1997)
  • America’s Top Physician, Guide to America’s Top Physicians by Consumers’ Research Council of America (2005, 2006, 2007)
  • J-1 Visa Waiver as Outstanding Researcher, United States Department of Health and Human Services for Outstanding research in the field of Prostate Cancer (2006)
  • Who’s Who in America, Marquis Who’s Who in America (2008)
  1. Savera AT, Linden MD: Solitary pulmonary nodule: Primary lung adenocarcinoma versus metastatic colonic carcinoma. Appl Immunohistochem, 1995; 3(4):272-275.
  2. Savera AT, Torres FX, Linden MD, Bacchi CE, Gown AM, Zarbo RJ: Primary versus metastatic pulmonary adenocarcinoma: An immunohistochemical study using villin and cytokeratins 7 and 20. Appl Immunohistochem, 1996; 4(2):86-94.
  3. Savera AT, Gown AM, Zarbo RJ: Immunolocalization of three novel smooth muscle-specific proteins in salivary gland pleomorphic adenoma: Assessment of the morphogenetic role of myoepithelium. Mod Pathol,1997; 10(11):1093-1100.
  4. Savera AT, Sloman A, Huvos AG, Klimstra DS: Myoepithelial carcinoma of the salivary glands. A clinicopathologic study of 25 cases. Am J Surg Pathol, 2000; 24(6): 761-774.
  5. Prasad AR, Savera AT, Gown AM, Zarbo RJ: The myoepithelial immunophenotype in 135 benign and malignant salivary gland tumors other than pleomorphic adenoma. Arch Pathol Lab Med, 1999;123:801-806.
  6. Zarbo RJ, Prasad AR, Regezi JA, Gown AM, Savera AT: Salivary gland Basal cell and Canalicular adenomas: Immunohistochemical demonstration of myoepithelial cell participation and morphogenetic considerations. Arch Pathol Lab Med 2000;14:401-405.
  7. Silbergleit R, Agrawal R, Savera AT, Patel S: Alveolar soft part sarcoma of the neck. Neuroradiology 2002;44:861-863.
  8. Rybicki BA, Savera AT, Gomez JA, Patel BS, Ballard NE, Benninger MS, Zarbo RJ, Van Dyke DL: Allelic loss and tumor pathology in head and neck squamous cell carcinoma. Mod Pathol 2003;16(10):970-979.
  9. Savera AT, Zarbo RJ: Defining the role of Myoepithelium in Salivary gland Neoplasia. Adv Anat Pathol 2004;11(2): 69-85.
  10. Rybicki BA, Rundle A, Savera AT, Sankey SS, Tang D: Polycyclic Aromatic Hydrocarbon-DNA Adducts in Prostate Cancer. Cancer Res. 2004 Dec 15;64(24):8854-8859.
  11. Coon SW, Savera AT, Zarbo RJ, Benninger MS, Chase GA, Rybicki BA, Van Dyke DL: Prognostic implications of loss of heterozygosity at 8p21and 9p21 in Head and Neck Squamous cell carcinoma. Int J Cancer 2004; 20; 111(2):206-212.
  12. Kaul S, Bhandari A, Hemal A, Savera A, Shrivastava A, Menon M: Robotic radical prostatectomy with preservation of the prostatic fascia: A feasibility study. Urology 2005 Dec;66(6):1261-5
  13. Boris R, McIntire L, Al-Assi O, Peabody JO, Savera AT: An unusual case of ureteral tumor in a duplex system. Int Urol Nephrol. 2006;38(3-4):473-4.
  14. Rybicki BA, Nock NL, Savera AT, Tang D, Rundle A: Polycyclic Aromatic Hydrocarbon-DNA adduct formation in prostate carcinogensis. Cancer Lett. 2006 Aug 8;239(2):157-67.
  15. Kaul S, Savera A, Badani K, Fumo M, Bhandari A, Menon M: Functional Outcomes and Oncologic Efficacy: An analysis of 154 consecutive patients undergoing Vattikuti Institute Prostatectomy with the Veil of Aphrodite nerve sparing. BJU Int. 2006 Mar;97(3):467-72.
  16. Savera AT, Kaul S, Badani K, Stark AT, Shah NL, Menon M: Robotic Radical Prostatectomy with the “Veil of Aphrodite” technique: Histologic evidence of enhanced nerve sparing. Eur Urol. 2006 Jun;49(6):1065-74.
  17. Tang D, Liu J, Rundle A, Neslund-Dudas C, Savera AT, Bock CH, Nock N, Yang JJ, Rybicki BA: Grilled meat consumption and PhIP-DNA adducts in prostate carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):803-8.
  18. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A, Kim JH. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther. 2007 May;15(5):1016-23.
  19. Nock NL, Tang D, Rundle A, Neslund-Dudas C, Savera AT, Bock CH, Monaghan KG, Koprowski A, Mitrache N, Yang JJ, Rybicki BA. Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race. Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1236-45.
  20. Tang D, Liu JJ, Bock CH, Neslund-Dudas C, Rundle A, Savera AT, Yang JJ, Nock NL, Rybicki BA. Racial differences in clinical and pathological associations with PhIP-DNA adducts in prostate. Int J Cancer. 2007 Sep 15;121(6):1319-24.
  21. Rybicki BA, Neslund-Dudas C, Bock CH, Rundle A, Savera AT, Yang JJ, Nock NL, Tang D. Polycyclic Aromatic Hydrocarbon-DNA Adducts in Prostate and Biochemical Recurrence after Prostatectomy. Clinical Cancer Research 2008 Feb 1;14(3):750-7.
  22. Worsham MJ, Raju UB, Lu M, Kapke A, Botttrell A, Cheng J, Shah V, Savera AT, Wolman SR. Risk Factors for breast cancer from benign breast disease in a diverse population. Breast Cancer Res Treat. 2009 Nov;118(1):1-7.
  23. Barnabas N, Xu L, Savera AT, Hou Z, Barrack ER. Chromosome 8 markers of metatstatic prostate cancer in African American men: Gain of the MIR151 gene and loss of the NKX3-1 gene. The Prostate 2011; 71:857-871.
  24. Rybicki BA, Neslund-Dudas C, Bock CH, Nock NL, Rundle AG, Jankowski M, Levin AM, Beebe-Dimmer JL, Savera AT, Takahashi S, Shirai T, Tang DL. Red Wine Consumption is inversely associated with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-DNA Adduct Levels in Prostate. Cancer Prev Res (Phila). 2011 Oct;4(10):1636-44.
  25. Randall B, Tindall C, Savera AT, Lindemann J: Perinatal alloimmune thrombo- cytopenia. (Michigan Association of Blood Banks, 1994 Annual meeting).
  26. Savera AT, Torres FX, Gown AM, Zarbo RJ: The diagnostic utility of cytokeratin 20 in the discrimination of primary pulmonary adenocarcinoma from colonic adenocarcinoma metastatic to the lung. (U.S. and Canadian Academy of Pathology, Toronto, Canada, 1995 Annual meeting). Mod Pathol 1995; 8:68A.
  27. Ma CK, Amin MB, Linden MD, Zarbo RJ, Savera AT, Wang NP, Gown AM: Comparative immunophenotypes of primary carcinomas of the kidney, adrenal and liver: An immunohistochemical study with a panel of antibodies to individual cytokeratins and other antigens (U.S. and Canadian Academy of Pathology, Toronto, Canada, 1995 Annual meeting). Mod Pathol 1995;8: 132A.
  28. Savera AT, Linden MD, Gown AM, Zarbo RJ: Use of monoclonal antibody to villin in differentiating primary versus metastatic adenocarcinomas of lung. (U.S. and Canadian Academy of Pathology, Toronto, Canada, 1995 Annual meeting). Mod Pathol 1995;8:153A.
  29. Savera AT, Ma CK, Nakhleh RE, Linden MD, Zarbo RJ: The utility of villin, cytokeratins 7 and 20 in the differential diagnosis of carcinoma in the liver. (American Society of Clinical Pathology, Orlando, FL, 1995 Spring Meeting). Am J Clin Pathol 1995;103:505.
  30. Savera AT, Raju UB, Linden MD: Mesothelioma vs Adenocarcinoma: Diagnostic utility of HBME-1. (U.S. and Canadian Academy of Pathology, Washington D.C., 1996 Annual meeting). Lab Invest 1996;74(1):952.
  31. Savera AT, Gown AM, Zarbo RJ: Immunohistochemical expression of hormone receptors in human salivary glands and pleomorphic adenomas. (U.S. and Canadian Academy of Pathology, Washington D.C., 1996 Annual meeting). Lab Invest 1996;74(1):602.
  32. Savera AT, Gown AM, Zarbo RJ: Immunolocalization of smooth muscle-specific proteins in pleomorphic adenomas. (U.S. and Canadian Academy of Pathology, Washington D.C., 1996 Annual meeting). Lab Invest 1996;74(1):603.
  33. Langel DJ, Zarbo RJ, Savera AT, Gown AM: Monoclonal antibodies to surfactant apoprotein A can distinguish between pulmonary and non-pulmonary adenocarcinomas. (U.S. and Canadian Academy of Pathology, Washington D.C., 1996 Annual meeting). Lab Invest 1996;74(1):931.
  34. Savera AT, Raju UB, Linden MD: Malignant mesothelioma versus pulmonary adenocarcinoma: An immunohistochemical evaluation (American Society of Clinical Pathology, Boston, MA, 1996 Spring Meeting). Am J Clin Pathol 1996;105(4):495.
  35. Savera AT, Varma M, Gown AM, Zarbo RJ: Brain metastases of pulmonary and breast adenocarcinomas: Discriminant value of monoclonal antibody to surfactant apoprotein A. (U.S. and Canadian Academy of Pathology, Orlando, Florida, 1997 Annual meeting). Lab Invest 1997;76(1):1007.
  36. Savera AT, Tamboli P, Amin MB, Ro JY, Nakhleh RE, Linden MD, Ayala AG: Ductal versus acinar differentiation in adenocarcinoma of prostate: Assessment of tumor proliferative index using MIB-1 immunostaining and mitotic count in 50 cases. (U.S. and Canadian Academy of Pathology, Orlando, Florida, 1997 Annual meeting). Lab Invest 1997;76(1):510.
  37. Savera AT, Amin MB, Ro JY, Linden MD, Ayala AG: Differential diagnosis of malignant neoplasms in the prostate with large ductal pattern: Utility of an immunohistochemical panel. (U.S. and Canadian Academy of Pathology, Orlando, Florida, 1997 Annual meeting). Lab Invest 1997;76(1):509.
  38. Anderson SS, Langel DJ, Gown AM, Prasad A, Savera AT, Zarbo RJ: Thyroid Transcription Factor-1 (TTF-1) is a more sensitive lung carcinoma marker than surfactant apoprotein A1. (U.S. and Canadian Academy of Pathology, 1998 Annual meeting). Mod Pathol 1998;11(1): 171A.
  39. Savera AT, Klimstra DS, Huvos AG: Myoepithelial carcinoma of salivary glands. A clinicopathologic study of 25 cases. (U.S. and Canadian Academy of Pathology, 1999 Annual meeting). Mod Pathol 1999;12(1): 130A.
  40. Savera AT, Huvos AG, Klimstra DS: Comparative analysis of the purported immunohistochemical “myoepithelial markers.” (U.S. and Canadian Academy of Pathology, 1999 Annual meeting). Mod Pathol 1999;12(1): 130A.
  41. Prasad AR, Savera AT, Regazi JA, Gown AM, Zarbo RJ: Immunohistochemical demonstration of myoepithelial cell participation in salivary gland basal cell and canalicular adenomas. (U.S. and Canadian Academy of Pathology, 1999 Annual meeting). Mod Pathol 1999;12(1): 130A.
  42. Prasad AR, Savera AT, Regazi JA, Zarbo RJ: Antimitrochondrial antibody – A diagnostic discriminant of salivary gland oncocytic tumors and acinic cell carcinomas. (U.S. and Canadian Academy of Pathology, 1999 Annual meeting). Mod Pathol 1999;12(1): 130A.
  43. Savera AT, Prasad AR, Zarbo RJ: Myoepithelial carcinoma of the breast: A clinicopathologic study of 18 cases. (U.S. and Canadian Academy of Pathology, 2000 Annual meeting). Mod Pathol 2000;13(3): 31A.
  44. Gomez JA, Savera AT, Rybicki BA, Vandyke DL, Benninger MS, Zarbo RJ: Loss of heterozygosity (LOH) correlates with tumor and host response parameters in head and neck squamous cell carcinoma. (U.S. and Canadian Academy of Pathology, 2000 Annual meeting). Mod Pathol 2000;13(3): 138A.
  45. Chitale DA, Lee MW, Linden MD, Savera AT, Lynn AAA, Raju, U: A comparison of primary mucinous carcinomas of breast and metastatic gastrointestinal mucinous carcinoma to skin. (U.S. and Canadian Academy of Pathology, 2001 Annual meeting). Mod Pathol 2001;14(1): 66A.
  46. Savera AT, Zarbo RJ: Mammary intraductal proliferations: A morphologic and immunohistochemical characterization. (U.S. and Canadian Academy of Pathology, 2001 Annual meeting). Mod Pathol 2001;14(1): 36A.
  47. Savera AT, Prasad AR, Zarbo RJ: Oncocytic Myoepithelioma of salivary glands: An under-recognized variant. (U.S. and Canadian Academy of Pathology, 2002 Annual meeting). Mod Pathol 2002;15(1): 224A.
  48. Savera AT, Zarbo RJ, Yaziji H, Barry T, Gown AM: Assessment of p63 as a myoepithelial marker using salivary gland pleomorphic adenoma. (U.S. and Canadian Academy of Pathology, 2003 Annual meeting). Mod Pathol 2003;16(1):222A.
  49. Wolman SR, Raju UB, Abrams J, Savera AT, Worsham MJ: Frequency and Distribution of benign breast lesions: Histopathology analysis of a multiethnic, primaryhealthcarederived benign breast disease casecontrol cohort. (American Society of Investigative Pathology, 2003 Annual Meeting)
  50. Worsham MJ, Abrams J, Raju UB, Mott D, Shah V, Savera AT, Cheng J, Wolman SR: Benign Breast Disease as a Risk for Breast Cancer in a Multi-Ethnic Cohort from a Primary Health Care Population. (American Association of Cancer Research, 2003 Annual Meeting)
  51. Inamdar KV, Linden MD, Savera AT: Assessment of the diagnostic utility of CD117/C-Kit and CD30 in the differential diagnosis of Non-seminomatous and Seminomatous testicular germ cell tumors. (U.S. and Canadian Academy of Pathology, 2005 Annual meeting, San Antonio, TX). Mod Pathol 2005;18(1):147-8A.
  52. Savera AT, Salama ME: Oncocytic Epithelial-Myoepithelial Carcinoma of the Salivary Gland. An unrecognized morphologic variant. (U.S. and Canadian Academy of Pathology, 2005 Annual meeting). Mod Pathol 2005;18(1):217A.
  53. Inamdar KV, Linden MD, Savera AT: OCT4 immunoreactivity in testicular germ cell tumors: Assessment of diagnostic utility and histogenetic implications. (U.S. and Canadian Academy of Pathology, 2005 Annual meeting). Mod Pathol 2005;18(1):148A
  54. Nelson F, Savera AT, Craig J, Bartol S, Little B, Martin S: Patterns of rapid focal bone response to osteoarthrosis. (Presented at the 52nd Annual Meeting, Orthopaedic Research Society, 2006).
  55. Savera AT, Kaul S, Badani K, Menon M: Robotic Radical Prostatectomy with the “Veil of Aphrodite” technique: Histologic evidence of enhanced nerve sparing. (Presented at the American Urological Association, 2006 Annual Meeting)
  56. Badani KK, Savera AT, Kaul S, Fumo M, Menon M: Whole mount pathological analysis of closest distance between tumor and resection margin after Robotic Prostatectomy: A comparison of standard nerve sparing versus lateral prostatic fascia sparing technique of nerve preservation. (Presented at the Minimally Invasive Robotic Association, International Congress, December 2005)
  57. Shah NL, Kaul S, Badani K, Savera AT, Menon M: Anterolateral fascia sparing robotic radical prostatectomy – The Super VIP: A novel nerve sparing technique for focal and functional patients. (Presented at the Minimally Invasive Robotic Association, International Congress, December 2005, Innsbruck, Austria)
  58. Savera AT, Kaul S, Badani K, Menon M: Robotic Vattikuti Institute Prostatectomy (VIP): A comparative histologic analysis of Standard nerve sparing and “Veil of Aphrodite” techniques. (Presented at the Minimally Invasive Robotic Association, International Congress, December 2005, Innsbruck, Austria)
  59. Nelson F, Savera AT, Craig J, Holley KG, Muldoon MP: Rapid focal osteoarthritis bone response in areas of concentrated force. (Presented at the American Orthopaedic Association, 119th Annual Meeting, June 2006).
  60. Badani KK, Savera AT, Kaul S, Fumo M, Menon M: Whole mount pathological analysis of closest distance between tumor and resection margin after Robotic Prostatectomy: A comparison of standard nerve sparing versus lateral prostatic fascia sparing technique of nerve preservation. (Presented at the American Urological Association, 2006 Annual Meeting)
  61. Tang D, Liu J, Savera AT, Rundle A, Neslund-Dudas C, Yu J, Yang JJ, Rybicki BA: PhIP-DNA Adducts As a Biomarker for Prostate Carcinogenesis. (Presented at the American Association of Cancer Research, 2006 Annual Meeting)
  62. Badani KK, Savera AT, Kaul S, Fumo M, Menon M: Closest distance between tumor and resection margin after Robotic Prostatectomy (RP): A pathological comparison of standard nerve sparing versus lateral prostatic fascia sparing technique of nerve preservation. (Presented at the World Congress of Endourology, 2006 Annual meeting)
  63. Rybicki BA, Neslund-Dudas C, Savera AT, Rundle A, Nock N, Bock C, Yang JJ Tang D: Increased PAH-DNA Adduct Levels are an Additional Predictor of Biochemical Recurrence in Prostatectomy Patients with Clinical Indicators for Poor Prognosis. (Presented at the American Association of Cancer Research, 2006 Annual Meeting)
  64. Rybicki BA, Liu J, Mitrache N, Neslund-Dudas C, Bock C, Rundle A, Savera AT, Yang JJ, Nock N, Tang D: Additive Effect of Diet and Genes in the 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) Metabolism Pathway and PhIP-DNA Adducts in Human Prostate. (Presented at the AACR Complex Pathways Meeting, 2007).
  65. Badani KK, Savera AT, Bhandari M, Menon M. Whole mount pathological analysis of closest distance between tumor and resection margin after Robotic prostatectomy: A comparison of standard nerve sparing versus lateral prostatic fascia sparing techniques of nerve preservation. (Presented at the American Urological Association, 2007 Annual Meeting).
  66. Savera AT. Small Focus of Atypical Glands: Utility of “Atypical Panel” and Expert Second Opinion. (PLUS Diagnostics Case Presentation Series, February 2011).
  67. Savera AT. Signet-Ring Adenocarcinoma: A Potential Diagnostic Pitfall. (PLUS Diagnostics Case Presentation Series, February 2011).
  68. Savera AT. PTEN deletion in “low risk” prostate cancer: Significance and Implications. (PLUS Diagnostics Case Presentation Series, August 2011).
  69. Riba AK, Savera AT. Comprehensive Diagnostic and Immunohistochemistry Utilization Data of Prostate Needle Biopsies: A National Pathology Laboratory Experience. Mod Pathol 2014;27(2):255A.
  70. Savera AT. Expert GU Pathology Consultation Data: Concordance analysis of Cases from In-Office Pathology Labs. Mod Pathol 2014;27(2):259A.
  71. Savera AT. ERG Oncoprotein Expression in Prostate Core biopsies: Diagnostic Utility and Correlation with the New Proposed Prognostic Gleason Grade Grouping. Mod Pathol 2014;27(2):259A.